Electroporation hydrogel patch for repairing skin injury
Through the electrotransfection technology of semi-implanted portable electroporation hydrogel patches, the problems of dermal regeneration and tissue reconstruction in large wounds are solved, and early repair and portability in large wounds are achieved, which significantly shortens the repair time.
Patent Information
- Application Number
- CN202411170922.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-07-26
- Filing Date
- 2024-08-23
- Publication Date
- 2024-12-03
AI Technical Summary
The prior art is difficult to achieve dermal cell regeneration and tissue reconstruction in large or deep wounds, and traditional repair methods require large equipment, affecting portability and repair time.
Design a semi-implanted miniaturized portable electroporated hydrogel patch including a foldable flexible circuit board and an alternative implantable stent module to transform TGF-β and VEGF through local electrical stimulation and electrotransfection techniques. -A plasmid is introduced into the wound surface to promote synchronous repair of the epidermis and dermis.
Early epidermal and dermal repair of large wounds has been achieved, shortening the repair time, and no need to rely on large equipment. Patients can operate on their own, improving the convenience of the medical process.
Smart Images

Figure CN119055954A_ABST
Abstract
Description
Priority application
[0001] This application claims priority to the Chinese invention patent application [CN2024110117513] "An electroporation hydrogel patch for repairing skin damage" filed on July 26, 2024, which is incorporated by reference in its entirety. Technical Field
[0002] The invention belongs to the field of medical engineering micro-nano equipment, and in particular relates to an electroporation hydrogel patch for repairing skin damage. Background Art
[0003] Large skin wounds have a large surface area (usually greater than 6 cm 2 ) and deep vertical depth (full-thickness skin). Clinically, large wounds repair significantly slower than small wounds and are more likely to cause other complications. At present, traditional methods for repairing large wounds include dressings, skin grafts, and ECM-like scaffolds. These methods can provide a wound healing environment (moist environment) and reduce the probability of wound infection during wound repair, but there is a problem of long repair time. The traditional method is to first perform wound plane healing (scab and epidermis formation), and then perform three-dimensional space repair (dermis reconstruction), that is, according to the order of occurrence. The repair of wound surface mainly includes three necessary periods: 1) the formation of blood scab at the wound, that is, a layer of blood scab is formed on the outer surface of the wound, which plays a role in stopping bleeding and reducing the exposure of the wound to the air; 2) the regeneration of the epidermis of the skin at the wound, that is, the proliferation and migration of healthy epidermal cells at the edge of the wound, and the cells migrate from the periphery of the wound to the center of the wound; 3) the regeneration of dermal cells and tissue reconstruction, that is, the proliferation, migration (cell regeneration) and differentiation (tissue reconstruction) of the related cells (such as fibroblasts and vascular epidermal cells) that constitute the dermis. The transition of these three periods is slow and promotes the repair of the wound surface in sequence, which is particularly obvious in the repair of large wounds.
[0004] The patent with publication number CN116807742A (20230929) and invention name "A flexible bioabsorbable bandage with a dual electrical stimulation system and a preparation method" discloses an absorbable flexible bandage consisting of an external pulse electrical stimulation system and a self-driven DC electrical stimulation system. The light-cured chitosan hydrogel of the bandage contains a target delivery substance, which can effectively accelerate wound healing. The patented method induces electrotransfected epithelial cells to promote the expression of healing factors through external pulse electrical stimulation to promote wound healing. However, the patented method can only achieve epidermal regeneration of the skin at the wound site in small or superficial wound scenarios, and cannot achieve dermal cell regeneration and tissue reconstruction in large or deeper wounds. In addition, the implementation of the patented method requires reliance on large equipment, such as a large electrotransfection instrument. Therefore, in order to shorten the repair time, it is necessary to promote the simultaneous promotion of wound plane healing and spatial tissue repair, and in order to promote the portability of the medical process, it is necessary to propose new methods and strategies. Summary of the invention
[0005] The purpose of the present invention is to provide a semi-implantable miniaturized portable electroporation hydrogel patch for repairing deep skin damage. The specific technical scheme is as follows.
[0006] A semi-implantable miniaturized portable electroporation hydrogel patch for repairing skin damage, the semi-implantable miniaturized portable electroporation hydrogel patch comprising an electroporation module and a replaceable implantable stent module; the electroporation module comprises a foldable flexible circuit board, a first electrode and a connection structure; the foldable flexible circuit board is fixed to the first electrode through a first wire, the first electrode is a hollow ring structure (for local electrical stimulation); the first electrode is nested in the connection structure; the foldable flexible circuit board comprises a circuit unit and a power supply; the circuit unit is a logic circuit unit component, and the logic circuit unit component adopts a pre-programmed microcontroller unit for controlling BLE communication and pulse operation;
[0007] The implantable stent module is degradable and includes a composite hydrogel stent and a second electrode. The composite hydrogel stent has a thickness capable of filling the depth of the wound. The top of the composite hydrogel stent is connected to the connection structure (when in use, the composite hydrogel stent can be released from the connection structure), and the second electrode is arranged at the bottom;
[0008] The second electrode is a hollow ring structure; the composite hydrogel scaffold is a porous sponge (having a certain thickness, used to fill the wound surface), and contains TGF-β plasmid and VEGF-A plasmid inside;
[0009] The foldable flexible circuit board is also provided with a second wire, and when in use, the second wire passes through the composite hydrogel support and contacts the second electrode;
[0010] The electrotransfer module is separated from the replaceable implantable stent module. After the electrotransfer is completed, the connection structure is removed, and the first wire and the second wire are removed at the same time, so that the electrotransfer module of the hydrogel patch and the implantable stent module are separated, the electrotransfer module can be reused, and the implantable stent module enters the wound surface.
[0011] Furthermore, the first electrode is a ring-shaped silver (Ag) electrode; the second electrode is a ring-shaped silver-magnesium (Ag-Mg) electrode; the silver-magnesium (Ag-Mg) electrode degrades faster.
[0012] Furthermore, the composite hydrogel is mainly made of methacrylamide gelatin and carboxymethyl chitosan, including 10% gelatin (GelMA) and 2% carboxymethyl chitosan (CMC), with a volume ratio of 1:1; a light curing agent (LAP) can also be added to the composite hydrogel.
[0013] Furthermore, the ratio of the TGF-β plasmid to the VEGF-A plasmid is 1:1, and the concentrations of both are 300 ng / μL.
[0014] Furthermore, the connection structure is a circular polyurethane film, and the size of the connection structure is larger than the first electrode.
[0015] Furthermore, the logic circuit unit component is also configured with an antenna capable of receiving wireless signals, such as a 2.4 GHz antenna; and the power source is a battery.
[0016] Furthermore, the microcontroller unit adopts nRF51822 chip.
[0017] Furthermore, the logic circuit unit component is configured to convert direct current into a stable direct current pulse wave with a voltage of 30V and a duration of 50ms.
[0018] Another aspect of the present invention is to provide a control system for controlling the semi-implantable miniaturized portable electroporation hydrogel patch to perform electroporation operations.
[0019] The control system includes a user interaction module 10, a machine operation module 20 and a terminal control module 30, wherein:
[0020] The user interaction module 10 is configured to receive a control instruction indicating a start triggered by a user, and control the electric conversion module in the machine operation module 20 to start operation according to the control instruction;
[0021] The terminal control module 30 is configured to output a control transmission signal to start the electric transfer module to transmit the pulse electric field after receiving the start instruction transmitted by the user interaction module 10; the pulse electric field has a voltage of 30V, a pulse number of 100 times, a duration of 50ms each time, and a buffer time of 50ms each time;
[0022] The machine operation module 20 is configured to perform electrotransfection on the TGF-β plasmid and VEGF-A plasmid contained in the composite hydrogel scaffold in the implantable scaffold module after receiving the control transmission signal sent by the terminal control module 30.
[0023] Furthermore, when the machine operation module 20 completes one electric rotation operation, it transmits an operation completion signal to the terminal control module 30 .
[0024] In some preferred embodiments, the terminal control module 30 may be a mobile phone APP.
[0025] The user can choose to perform the electroporation operation once or multiple times according to the display on the terminal control module 30 (for example, completion of the electroporation operation).
[0026] Beneficial technical effects
[0027] The present invention provides a semi-implanted miniaturized portable electroporation hydrogel patch (hereinafter referred to as the device) for repairing deep skin damage, which includes a reusable electroporation module and a replaceable implantable stent module. In animal experiments, it is proved that the two modules of the electroporation hydrogel patch of the present invention can work synergistically, effectively electrotransfect local cells at the wound site, so that TGF-β plasmid and VEGF-A plasmid are successfully electrotransfected into the cells at the edge of the wound and expressed, and the cells produce TGF-β and VEGF-A and secrete them into the wound microenvironment to bring about cell proliferation and angiogenesis effects; and the filling of the hydrogel in the wound not only enhances cell proliferation, but also provides a porous environment for cells to migrate in a specific path, realizing the synchronous advancement of early repair of the epidermis (plane) and dermis (space), and finally realizing the synchronous advancement of epidermal and dermal repair of large wounds or deep wounds, the repair time is faster, and the final average blood vessel area is not significantly different from the average blood vessel area of the healthy group.
[0028] Specifically, the device of the present invention first provides local electrical stimulation of the skin around the wound, and the plasmid expresses TGF-β and VEGF-A in the locally electrically stimulated cells, which is beneficial to the regeneration of epidermal and dermal cells, and provides a large amount of cell support for the spatial healing of the skin epidermis and dermis. The hydrogel that swells after absorbing water can be seamlessly pressed on the wound surface and fit with the wound, playing a role of physical sealing, while paving a shorter path for the cells at the edge of the wound to migrate to the wound. In addition, the hydrogel scaffold also has a certain thickness, which is conducive to the rapid bonding of the tissue-hydrogel interface. As a filler with a certain thickness, it provides a favorable microenvironment for cell migration and colonization. After the plasmid expresses TGF-β and VEGF-A proteins in the cells, it accelerates the migration of cells to the center of the hydrogel. The distribution and growth differentiation of dermal cells in the vertical depth of the wound avoids the detour of the conventional cell migration pathway, overcomes the main spatial obstacles to skin regeneration, and thus achieves the effect of faster wound closure.
[0029] Finally, the present invention proposes to apply electrotransfection operation to the field of deep skin wound repair, and provides a semi-implantable miniaturized device, so that patients do not need to rely on large equipment from professional institutions, and can choose to perform autonomous operations, making the medical process more convenient. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] In order to more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings required for use in the embodiments or the prior art descriptions are briefly introduced below. In all the drawings, similar elements or parts are generally identified by similar reference numerals. In the drawings, each element or part is not necessarily drawn according to the actual scale. Obviously, the drawings described below are some embodiments of the present invention. For those of ordinary skill in the art, other drawings can also be obtained based on these drawings without paying creative labor.
[0031] Figure 1 This is a schematic diagram of the overall structure of an electroporation hydrogel patch in one embodiment of the present invention;
[0032] Figure 2 This is a schematic diagram of the connection structure of an electroporation hydrogel patch in one embodiment of the present invention;
[0033] Figure 3 A schematic diagram of a foldable flexible circuit board structure in one embodiment of the present invention;
[0034] Figure 4 A schematic diagram of the working principle of the electroporation hydrogel patch in one embodiment of the present invention;
[0035] Figure 5 This is a working diagram of an electroporation hydrogel patch in one embodiment of the present invention;
[0036] Figure 6 This is a rendering of the effect of the hydrogels with different components fitting the wound surface in one embodiment of the present invention;
[0037] Figure 7 A fluorescent image of a transfected tissue region in one embodiment of the present invention;
[0038] Figure 8 This is a picture of early-stage cells accumulated at the edge of the gel in an animal experiment in one of the embodiments of the present invention;
[0039] Fig. 9 This is a result diagram of the number of cell proliferation at the wound surface after different treatments in one embodiment of the present invention;
[0040] Fig.10 This is a result diagram of angiogenesis at the wound surface after different treatments in one embodiment of the present invention;
[0041] Fig.11 This is a picture of wound repair and healing in a rat experiment in one of the embodiments of the present invention;
[0042] Fig.12 This is a picture of wound repair and healing in a pig experiment in one of the embodiments of the present invention;
[0043] Fig.13 Schematic diagram of a control system for controlling a miniaturized portable electroporation hydrogel patch to perform electroporation operations in one embodiment of the present invention.
[0044] Summary of reference numerals:
[0045] 100 is a protective shell, 200 is a foldable flexible circuit board, 210 is a circuit unit, 220 is a power source, 230 is a wire hole, 300 is a first electrode, 400 is a connecting structure, 500 is a composite hydrogel scaffold, and 600 is a second electrode. DETAILED DESCRIPTION
[0046] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.
[0047] Herein "and / or" includes any and all combinations of one or more of the associated listed items.
[0048] Herein, "plurality" means two or more than two, ie, it includes two, three, four, five, etc.
[0049] It should be noted that, in this article, the terms "include", "comprises" or any other variations thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device. In the absence of further restrictions, an element defined by the sentence "comprises a ..." does not exclude the existence of other identical elements in the process, method, article or device including the element.
[0050] As used in this specification, the term "about" typically means + / - 5% of the stated value, more typically + / - 4% of the stated value, more typically + / - 3% of the stated value, more typically + / - 2% of the stated value, even more typically + / - 1% of the stated value, and even more typically + / - 0.5% of the stated value.
[0051] In this specification, some embodiments may be disclosed in a format of being within a certain range. It should be understood that such description of "being within a certain range" is only for convenience and brevity, and should not be interpreted as a rigid limitation on the disclosed range. Therefore, the description of the range should be considered to have specifically disclosed all possible sub-ranges and independent numerical values within this range. For example, the range The description of should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within this range, for example, 1, 2, 3, 4, 5, and 6. The above rules apply regardless of the breadth of the range.
[0052] Example 1
[0053] This embodiment provides an example of an electroporation hydrogel patch.
[0054] A miniaturized portable electroporation hydrogel patch, which is a wirelessly controlled electronic skin wound repair patch, as shown in the schematic diagram Figure 1-Figure 3 The electroporation hydrogel patch includes an electroporation module (hereinafter referred to as ET module) and an implantable stent module (hereinafter referred to as IS module), and the electroporation module and the implantable stent module are separable.
[0055] The electric conversion module includes a foldable flexible printed circuit board (PCB) 200, the foldable flexible printed circuit board 200 includes a circuit unit 210 and a power supply 220, and the foldable flexible printed circuit board 200 is placed inside the protective housing 100. The electric conversion module may also include a first electrode 300, and the first electrode 300 is connected and fixed to the foldable flexible printed circuit board 200 through a wire (not shown). The electric conversion module may also include a connection structure 400, and the first electrode 300 is nested inside the connection structure 400.
[0056] In some preferred embodiments, the protective housing 100 is a transparent housing.
[0057] In some preferred embodiments, the first electrode 300 is a ring-shaped silver (Ag) electrode.
[0058] In some preferred embodiments, the connection structure 400 is a polyurethane film having a microporous array and a recess formed by laser cutting, the microporous array is used for ventilation, and the recess is used for nesting the first electrode 300. When in use, the connection structure 400 contacts the skin around the wound surface and is applied to the skin wound.
[0059] The implantable stent module includes a composite hydrogel (GCMCS) stent 500 and a second electrode 600. The second electrode 600 is disposed at the bottom of the composite hydrogel stent 500. The composite hydrogel stent 500 contains a TGF-β plasmid and a VEGF-A plasmid; in some preferred embodiments, the ratio of the two plasmids is 1:1. The foldable flexible circuit board 200 passes through the composite hydrogel stent 500 through a wire (not shown) and contacts the second electrode 600.
[0060] In some preferred embodiments, the second electrode 600 is a ring-shaped silver-magnesium (Ag-Mg) electrode.
[0061] The first electrode 300 and the second electrode 600 form a closed circuit.
[0062] In some preferred embodiments, the composite hydrogel is made of methacrylamide gelatin and carboxymethyl chitosan.
[0063] In some preferred embodiments, the foldable flexible circuit board 200 includes a circuit unit 210, a power supply 220 and a wire hole 230. The logic circuit unit components and the power supply (battery) are installed on two independent layers. The circuit unit uses a pre-programmed microcontroller unit (MCU) (Nordic Semiconductor nRF51822 chip) to control BLE communication and pulse operation. With a 2.4GHz antenna, it wirelessly receives a start signal from a smartphone APP, and controls the power supply by outputting a control transmission signal to turn on the power supply to control the plasmid in the composite hydrogel scaffold 500 for electrotransfer.
[0064] In some preferred embodiments, the electroporation module is reusable, has a diameter of 3 cm, and a height of about 7 mm.
[0065] In some preferred embodiments, the miniaturized portable electroporation hydrogel patch has a total weight of about 8.9 g.
[0066] Example 2
[0067] This embodiment provides an example of a control system for controlling the electroporation hydrogel patch of embodiment 1 to perform electroporation operation. The system schematic diagram is shown in Fig.13 .
[0068] The control system includes a user interaction module 10, a machine operation module 20 and a terminal control module 30.
[0069] The user interaction module 10 is configured to receive a control instruction indicating a start triggered by a user, and control the electric conversion module in the machine operation module 20 to start operation according to the control instruction.
[0070] The terminal control module 30 is configured to output a control transmission signal to start the electric transfer module to transmit the pulse electric field after receiving the start instruction transmitted by the user interaction module 10; the pulse electric field has a voltage of 30V, 100 pulses, each lasting 50ms, and a buffer time of 50ms each time.
[0071] The machine operation module 20 is configured to perform electrotransfection on the TGF-β plasmid and VEGF-A plasmid contained in the composite hydrogel scaffold in the implantable scaffold module after receiving the control transmission signal sent by the terminal control module 30.
[0072] When the machine operation module 20 completes one electric rotation operation, it transmits an operation completion signal to the terminal control module 30 .
[0073] Next, the effect of the control system after completing one electric transfer operation is verified.
[0074] Use the mobile phone to open Bluetooth to connect the electroporation hydrogel patch and start electrotransfection. The specific operation is 30V voltage, 100 pulses, 50ms duration each time, and 50ms buffer time each time. Stop transfection after 100 pulses, remove the electroporation module (including the connection structure) and the wire. The hydrogel scaffold can fill the entire wound space (such as Figure 4 and Figure 5 As shown), a matrix is provided to change the direction of cell migration, so that cells migrating downward can be changed to parallel migration, shortening the migration path.
[0075] About 3 days after electrotransfection, the transfected cells entered the center of the wound. Two weeks later, the implanted gel was completely degraded and the wound was completely healed.
[0076] Example 3
[0077] This embodiment provides an example of a method for preparing the electroporation hydrogel patch of Embodiment 1.
[0078] The specific design and production process of the ET module is as follows:
[0079] (1) Electronic components were soldered on a flexible printed circuit board at 138°C using solder paste (CD-LT528, Conduction, China).
[0080] (2) The microcontroller unit (MCU) uses the Nordic Semiconductor nRF51822 chip, which has a 32-bit Cortex TM M0 CPU with 256kB flash + 16kB RAM.
[0081] (3) The circuit has two power supply modes: (1) ten series-connected batteries (30 V) or (2) a single battery with a boost circuit (3.7 V). The boost circuit uses a boost converter (LM2733XMF, Texas Instruments) to boost a low voltage (3.0 V) to a high voltage (30 V). The buck circuit is used to reduce the high voltage (> 3.0 V) to a low voltage (3.0 V) through an LDO chip (MST5433BTS) to ensure the normal operation of the entire circuit.
[0082] (4) Output control is implemented by PMos (NCE60P04Y, 60V / 4A), and the pulse signal is transmitted by MCU.
[0083] (5) The protective shell is designed and drawn using CAD software and printed out using transparent resin.
[0084] Composite hydrogel preparation process:
[0085] (1) Dissolve gelatin methacrylate solid (1 g, GelMA) in ultrapure water (10 mL) in a 60°C water bath.
[0086] (2) Carboxymethyl chitosan powder (0.25 g, CMCS) was added to ultrapure water (10 mL). 0.25% lithium phenyl (2,4,6-trimethylbenzoyl) phosphinate (LAP) was then added to a 1:1 v / v mixture of 10% GelMA solution and 2% CMCS solution to prepare a final mixture of 5% GelMA / 1% CMCS / 0.025% LAP (GCMCS).
[0087] (3) The final mixture was placed at room temperature, injected into a hollow cylindrical mold (1.2 cm or 3 cm in diameter), and cured with ultraviolet light at a wavelength of 405 nm for 10 seconds to obtain a composite hydrogel.
[0088] (4) The solidified composite hydrogel was stored in a -20°C refrigerator overnight and freeze-dried in a freeze dryer for 6 hours to obtain a dry GCMCS sponge. The dried GCMCS sponge was stored in a dry environment at room temperature.
[0089] It is understood that when used, the dry GCMCS sponge can be converted back to a hydrogel state by soaking it in physiological saline containing plasmids.
[0090] Silver-magnesium (Ag-Mg) electrode preparation:
[0091] Ring electrodes were pierced from 50 μm thick Mg sheets with ring blades of different sizes. The surface oxide was carefully sanded with sandpaper. Ag was sputter deposited on one side of the Mg ring at 120 W.
[0092] Example 4
[0093] In vivo electroporation experiments based on Example 1 and Example 2
[0094] First, the hydrogel was screened:
[0095] The GCMCS composite hydrogel and the single GelMA hydrogel were applied to the skin wound respectively. At 0h and 12h, the wound skin was sliced for tissue, and the adhesion between the skin and the hydrogel was observed with the help of an optical microscope. Among them, the GCMCS composite hydrogel was prepared with a concentration of 10% GelMA and 2% CMCS photocuring agent, in which GelMA (10%) and CMCS (2%) each accounted for half of the total volume, and the photocuring agent LAP accounted for 0.25% of the total volume. The role of LAP is to link the GelMA monomers to each other, so that the morphology changes from liquid to solid. The results are as follows Figure 6As shown in the figure, there is a large gap between the GelMA hydrogel and the skin after application, while the GCMCS composite hydrogel is more tightly attached. The GCMCS composite hydrogel can be seamlessly pressed on the wound surface and adhere to the wound, playing a role of physical sealing, while paving a shorter path for cells at the edge of the wound to migrate to the wound. Therefore, GCMCS hydrogel was selected for subsequent experimental operations.
[0096] GCMCS hydrogel biosafety verification:
[0097] GCMCS hydrogel can be completely degraded and eventually degraded into amino acids and sugars that can be reused by organisms. The present invention team verified in cell experiments that the composite hydrogel cultured in vitro had no toxic side effects on dermal fibroblasts (L929) and vascular endothelial cells (RAEC). The high porosity of the composite hydrogel is conducive to cell migration, and it also has appropriate water absorbency and swelling capacity. Lyophilization (freeze drying) of GCMCS hydrogel can make 3D scaffolds easy to store for a long time and the shape can be customized. The excellent water absorbency (>50 times) enables the resulting dry sponge to restore its original hydrogel state and size by rehydration within 0.5 hours; the swelling ability of the hydrogel continues to expand the diameter of the thermogel scaffold by 9.8% within the first 12 hours after further absorbing liquid (e.g., wound exudate).
[0098] Electrotransfection experiment verification:
[0099] As shown in the figure, after the electroporation hydrogel patch was implanted in the body and the electrotransfection experiment was carried out for 3 days, the transfected tissue was taken for tissue cryosectioning, and the plasmid transfection was observed under fluorescence microscopy. Figure 7 The green fluorescent area represents the successful electro-transfection of TGF-β plasmid into the wound edge cells and its expression, and the red fluorescent area represents the successful expression of VEGF-A plasmid. Figure 8 The figure shows the number of cells migrating at the wound edge in the experimental group and the GCMCS hydrogel group alone 2 days after electrotransfection, where the arrows indicate the number of parenchymal cells in the dermis migrating to the wound edge. It can be seen that the number of cells in the experimental group is significantly greater than that in the pure hydrogel group.
[0100] In order to further verify the cell proliferation and angiogenesis effects brought about by the electroporated hydrogel patch transfecting TGF-β and VEGF-A plasmids into the dermal cells at the edge of the wound, the cells produced TGF-β and VEGF-A and secreted them into the wound microenvironment. The skin wounds were treated with four different methods: gauze treatment, hydrogel treatment only, hydrogel plus empty electrotransfection (without plasmid) treatment, and hydrogel plus electrotransfection (with plasmid) treatment. Wound samples were collected on the 7th and 14th days and compared with the cell number and angiogenesis area of the healthy group skin. Fig. 9 and Fig.10 shown. Fig. 9 The results showed that the hydrogel electrotransfection (containing plasmid) group had the most cells at 7 days and had significant differences with other groups, indicating that the cells in the early experimental group could enter the center of the wound the fastest and fill the wound, and the cells at the wound would further perform their functions (secreting collagen and forming blood vessels). At 14 days, the cells in the experimental group had completed their functions and the wound repair entered the final remodeling phase. The number of cells decreased and had no significant difference with the number of cells in the healthy group, indicating that the repair of the experimental group was nearly complete after 14 days. The number of cells in the control group (gauze group) increased at 14 days compared to 7 days, indicating that the control group had not yet completed the accumulation of cells in the wound and the wound repair was slow. Fig.10 It also shows the average area of blood vessels at the center of the wound. The average area of blood vessels in the hydrogel plus electrofection (containing plasmid) group is the largest and significantly different from other components, indicating that electrofection accelerates cell migration and blood vessel formation, and the porous environment of the hydrogel provides a location for blood vessel formation. At 14 days, there is no significant difference in the average blood vessel area of the experimental group and the healthy group, indicating that the wound repair in the experimental group was nearly complete at 14 days.
[0101] Example 6
[0102] Animal experiment verification
[0103] Rat experiment: 5-week-old male SD rats (200 g) were anesthetized and their dorsal hair was removed. Four circular full-thickness excisional wounds with a diameter of 1.2 cm were made in the dorsal skin of each rat (2×2 array) and divided into 2 groups: (1) a control group treated with conventional gauze method, and (2) a hydrogel patch group that was electro-transfected with pEGFP-rTgfb1 and pmCherry-rVegfa immediately after implantation. Each treatment was implemented at a different position of the 2×2 array in different rats, so the results would not be biased by different skin areas. Photographs of the wound area were taken on days 0, 3, 7, 12, and 14, and wound samples were collected on days 3, 7, 12, and 14 to evaluate wound healing. The results are shown in the table below. Fig.11 shown.
[0104] Pig experiment: Female Bama pigs (20 kg) several months old were anesthetized, their dorsal hair was removed, and the dorsal skin was disinfected. Six circular full-thickness incisions with a diameter of 3.0 cm were made on the dorsal skin of each pig (3 on each side of the spine) and divided into 2 groups: (1) a control group treated with conventional gauze method, and (2) a hydrogel patch group (General Biol, Anhui, China) that was electro-transfected with pEGFP-pTgfb1 and pmCherry-pVegfa immediately after implantation. In a 2 × 3 array, different groups were arranged in a criss-cross manner, so that the results would not be biased by different skin areas. Photos of the wound area were taken on days 0, 7, 14, 21, and 28, and wound samples were collected on days 7, 14, 21, and 28 to evaluate wound healing. The results are shown in Figure 2. Fig.12 shown.
[0105] In summary, the portable hydrogel patch provided by the present invention integrates in situ electrotransfection and 3D scaffolds into a ready-to-use device, combining the time and space advantages of tissue regeneration therapy, which can be operated from a smartphone via Bluetooth. The self-powered electrotransfection device stably outputs 100 pulses (each pulse duration is 50ms) at 30V in a single transmission event to achieve safe electroporation of cells at the edge of the wound. Transient transfection of plasmids enables cells to endogenously produce TGF-β1 and VEGF-A and secrete them into the wound microenvironment for up to 2 weeks. By filling the wound with a biocompatible 3D porous scaffold, the hydrogel patch eliminates the hemostasis period and shortens the migration path of migrating cells. When the two selective growth factors for tissue repair are overexpressed on the third day after device implantation, they enhance the proliferation and migration of dermal cells (mainly dermal fibroblasts and vascular endothelial cells) to the center of the wound, thereby promoting wound healing to enter the proliferation stage ahead of schedule, achieving advantages in time and space. That is, in the vacancy after the large wound is formed, the epidermis migrates parallel to the upper layer of the material, the required migration path becomes shorter, and the dermal cells can be evenly filled in the wound. Because the material is porous (porosity is 82%), it provides a migration site for dermal fibroblasts. Local electroporation makes the migration and growth of dermal cells faster, and the time required for cells to fill the wound is also less. Finally, the re-epithelialization of the rat model was achieved one week earlier, and the re-epithelialization of the pig model was achieved about two weeks earlier. The repair time of the two model animals was nearly 50% faster than the existing technology. The number of blood vessels and cells and the collagen content in the final wound were similar to those of healthy skin.
[0106] The embodiments of the present invention are described above in conjunction with the accompanying drawings, but the present invention is not limited to the above-mentioned specific implementation modes, which are merely illustrative rather than restrictive. Under the guidance of the present invention, ordinary technicians in this field can also make many forms without departing from the scope of protection of the present invention and the claims, all of which are within the protection of the present invention.
Claims
1. A semi-implantable miniaturized portable electroporation hydrogel patch, characterized in that: The semi-implantable miniaturized portable electroporation hydrogel patch includes an electroporation module and a replaceable implantable stent module; the electroporation module includes a foldable flexible circuit board, a first electrode and a connection structure; the foldable flexible circuit board is fixed to the first electrode through a first wire, and the first electrode is a hollow ring structure; the first electrode is nested in the connection structure; the foldable flexible circuit board includes a circuit unit and a power supply; the circuit unit is a logic circuit unit component, and the logic circuit unit component uses a pre-programmed microcontroller unit to control BLE communication and pulse operation; The implantable stent module is degradable and includes a composite hydrogel stent and a second electrode; the composite hydrogel stent has a thickness capable of filling the depth of the wound, the top of the composite hydrogel stent is connected to the connection structure, and the bottom is provided with the second electrode; the second electrode is a hollow ring structure; the composite hydrogel stent is porous sponge-like and contains TGF-β plasmid and VEGF-A plasmid inside; The foldable flexible circuit board is also provided with a second wire, and when in use, the second wire passes through the composite hydrogel support and contacts the second electrode; The electroporation module and the replaceable implantable stent module are separable.
2. The semi-implantable miniaturized portable electroporation hydrogel patch according to claim 1, characterized in that: The first electrode is a ring-shaped silver electrode; the second electrode is a ring-shaped silver-magnesium electrode.
3. The semi-implantable miniaturized portable electroporation hydrogel patch as claimed in claim 1, characterized in that The composite hydrogel comprises gelatin with a concentration of 10% and carboxymethyl chitosan with a concentration of 2%, with a volume ratio of 1:1; a light curing agent can also be added to the composite hydrogel.
4. The semi-implantable miniaturized portable electroporation hydrogel patch according to claim 1, characterized in that: The ratio of the TGF-β plasmid to the VEGF-A plasmid was 1:1, and the concentrations were both 300 ng / μL.
5. The semi-implantable miniaturized portable electroporation hydrogel patch according to claim 1, characterized in that: The connection structure is a polyurethane film, and the size of the connection structure is larger than the first electrode.
6. The semi-implantable miniaturized portable electroporation hydrogel patch according to claim 1, characterized in that: The logic circuit unit assembly is also equipped with an antenna capable of receiving wireless signals.
7. The semi-implantable miniaturized portable electroporation hydrogel patch according to claim 6, characterized in that: The microcontroller unit adopts nRF51822 chip.
8. The semi-implantable miniaturized portable electroporation hydrogel patch according to claim 1, characterized in that: The logic circuit unit component is configured to convert direct current into a stable direct current pulse wave with a voltage of 30V and a duration of 50ms.
9. A control system for controlling the semi-implantable miniaturized portable electroporation hydrogel patch according to any one of claims 1 to 8 to perform electroporation operations, characterized in that: The control system includes a user interaction module 10, a machine operation module 20 and a terminal control module 30: The user interaction module 10 is configured to receive a control instruction indicating a start triggered by a user, and control the electric conversion module in the machine operation module 20 to start operation according to the control instruction; The terminal control module 30 is configured to output a control transmission signal to start the electric transfer module to transmit the pulse electric field after receiving the start instruction transmitted by the user interaction module 10; the pulse electric field has a voltage of 30V, a pulse number of 100 times, a duration of 50ms each time, and a buffer time of 50ms each time; The machine operation module 20 is configured to perform electrotransfection on the TGF-β plasmid and VEGF-A plasmid contained in the composite hydrogel scaffold in the implantable scaffold module after receiving the control transmission signal sent by the terminal control module 30.
10. The control system according to claim 9, characterized in that: When the machine operation module 20 completes one electric rotation operation, it transmits an operation completion signal to the terminal control module 30 .
Citation Information
Cited By
Wireless wearable electrical stimulation microsystem for cell infection research
CN120617820A
